bemnifosbuvir + ruzasvir — Topline data
Q1 2027
Topline results are expected in early Q1 2027 and will provide additional efficacy data across a broader range of HCV genotypes more commonly found outside of the US and Canada.Source filing
AVIR biotech catalysts & pipeline
ATEA PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
bemnifosbuvir + ruzasvir — NDA/BLA submission
Q2 2027
Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.Source filing